Trials / Completed
CompletedNCT00266669
Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon
Phase III "in-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 200 (planned)
- Sponsor
- MediQuest Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the efficacy and safety of a topical gel formulation of nitroglycerin, in comparison to a matching placebo, for patients with moderate to severe primary Raynaud's phenomenon or patients with Raynaud's phenomenon secondary to autoimmune diseases, such as scleroderma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Topical organogel with nitroglycerin |
Timeline
- Start date
- 2005-12-01
- Completion
- 2006-05-01
- First posted
- 2005-12-19
- Last updated
- 2007-08-08
Locations
19 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00266669. Inclusion in this directory is not an endorsement.